Dr. Dale Schenk to Discuss Parkinson's Disease at 2014 Rejuvenation Biotechnology Conference
18 août 2014 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Aug. 18, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel...
Prothena Reports Second Quarter 2014 Financial Results and R&D Progress
04 août 2014 16h05 HE
|
Prothena Corporation plc
Completion of successful public equity offering netting $102.5 million and net cash provided by operating activities of $6.2 million in second quarter 2014 contributed to strengthen cash position...
Initiation of Multiple Ascending Dose Phase 1 Study of PRX002 in Patients With Parkinson's Disease
31 juil. 2014 16h05 HE
|
Prothena Corporation plc
First Patient with Parkinson's Disease Successfully Dosed in Second Phase 1 Study
Trial Designed to Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity
Multiple Biomarkers...
Prothena Announces Pricing of Public Offering of 4,750,000 Ordinary Shares
25 juin 2014 08h00 HE
|
Prothena Corporation plc
DUBLIN, Ireland, June 25, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel...
Prothena Announces Proposed Offering of Ordinary Shares
23 juin 2014 16h17 HE
|
Prothena Corporation plc
DUBLIN, Ireland, June 23, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel...
Prothena to Present at the Jefferies 2014 Global Healthcare Conference in New York
27 mai 2014 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, May 27, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel...
Prothena Reports First Quarter 2014 Financial Results and Provides R&D Updates
05 mai 2014 16h05 HE
|
Prothena Corporation plc
Encouraging cardiac biomarker responses from ongoing Phase 1 of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction presented at ISA
Additional Phase 1 data updates of...
Prothena to Host Webcast and Conference Call to Discuss Interim Phase 1 Data of Ongoing NEOD001 Study in Patients With AL Amyloidosis on May 2
01 mai 2014 16h05 HE
|
Prothena Corporation plc
DUBLIN, May 1, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies...
Prothena Announces Appointment of Chief Legal Officer
30 avr. 2014 16h30 HE
|
Prothena Corporation plc
DUBLIN, Ireland, April 30, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel...
Prothena's NEOD001 Demonstrates Encouraging Cardiac Biomarker Responses in Ongoing Phase 1 Study in Patients With Immunoglobulin Light Chain (AL) Amyloidosis
23 avr. 2014 11h44 HE
|
Prothena Corporation plc
NEOD001 appears generally safe, well-tolerated, has acceptable pharmacokinetic properties and no immunogenicity at studied dose levels
No dose limiting toxicities have been observed
Eight...